Keith Edwards appointed CEO of N2 Biomedical
BEDFORD, Mass., June 29, 2021 / PRNewswire / – N2 Biomedical, a leading provider of coating and surface treatment solutions for the medical device industry, is pleased to announce that Keith edwards was appointed general manager. Mr. Edwards will assume leadership of all aspects of the organization and oversee the implementation of N2’s growth strategy.
Mr. Edwards brings extensive expertise to this role, with over 20 years of experience in the medical device industry and a particular focus on the orthopedic market. Most recently, he was Executive Vice President and General Manager of Hamilton Thorne, Ltd. Orthopedics during his five-year tenure. He graduated from Union College and assisted New York College of Medicine.
“Keith’s extensive experience in the orthopedic space makes him an ideal candidate for his role at N2, and we are delighted to welcome him at this point in the evolution of N2,” said Trevor Wahlbrink, partner at Ampersand Capital Partners and member of the board of directors. “He has proven his ability to lead innovative service companies and has personally overseen thoughtful growth and expansion in this market. Under Keith’s leadership, N2 is well positioned to continue bringing its innovative coating and surface treatment technologies to the medical device market.
Mr. Edwards commented: “N2 Biomedical offers an excellent surface treatment offering, a superb culture and a team committed to the excellence and success of every customer. I look forward to advancing the organic growth of N2 and supporting our dedicated team.
About N2 Biomedical
Founded in 2013, N2 provides coating and surface treatment development and application services for implantable and other medical devices used in orthopedic, cardiovascular and other healthcare end markets. N2 is ISO-13485 certified, FDA GMP compliant, and operates in a 27,000 square foot facility with laboratory, manufacturing, and cleanroom space to meet all customer and regulatory requirements. The company leverages its proprietary processes and equipment to provide customized solutions that improve the characteristics of various materials in critical applications, including lubricity, resistance to infection, biocompatibility and tissue integration, as well as strength. wear and corrosion. Additional information on N2 Biomedical is available at www.n2bio.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a mid-market private equity firm with more than $ 2 billion assets under management dedicated to growth investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operational experience to create value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped create many market-leading companies in each of the major areas of corporate health. Additional information about Ampersand is available at www.ampersandcapital.com.
SOURCE Esperluette Capital Partners